A hybrid quantum-classical fusion neural network to improve protein-ligand binding affinity predictions for drug discovery
0
🧠
Sign in to get full access
Overview
- Drug discovery relies on accurately predicting the binding affinity between potential drug molecules and target proteins related to disease.
- Estimating binding affinity requires significant resources, and while classical machine learning (ML) techniques are used, emerging hybrid quantum machine learning (QML) models show promise for improved performance.
- Existing models face issues with convergence stability and prediction accuracy.
- This paper introduces a novel hybrid quantum-classical deep learning model for binding affinity prediction in drug discovery.
Plain English Explanation
When developing new drugs, it's crucial to understand how well potential drug molecules will bind to the proteins in the body that are involved in causing a disease. This binding affinity is difficult and expensive to measure accurately. While traditional machine learning methods have been used, new approaches that combine classical and quantum machine learning techniques have shown they can do a better job.
However, even these newer hybrid models have problems - they don't always converge properly during training, and their predictions aren't as accurate as they could be. This research paper presents a novel model that integrates 3D and spatial graph convolutional neural networks within an optimized quantum architecture.
The key idea is to leverage the unique properties of quantum computing, like its inherent parallelism and ability to handle high-dimensional data, to enhance the performance of this deep learning model for predicting binding affinity. The results show this approach can improve prediction accuracy by 6% compared to existing classical models, and also demonstrates more stable convergence during training.
Technical Explanation
The proposed model synergistically integrates 3D and spatial graph convolutional neural networks within an optimized quantum architecture. This allows the model to effectively capture the complex 3D spatial relationships and graph-based connectivity inherent in protein-ligand binding interactions.
The quantum component of the architecture leverages the inherent parallelism and exponential data representation capabilities of quantum computing to enhance the model's ability to handle the high-dimensional inputs and complex nonlinear relationships present in binding affinity prediction tasks. This hybrid quantum-classical approach is designed to provide more stable convergence and improved prediction accuracy compared to classical deep learning models.
Simulation results demonstrate a 6% improvement in binding affinity prediction accuracy relative to existing classical models. Additionally, the proposed model exhibits significantly more stable convergence performance compared to previous classical approaches, which is a crucial characteristic for practical deployment in drug discovery workflows.
Critical Analysis
The paper acknowledges that while the proposed model shows promising results, there are still areas for further research and improvement. For example, the authors note that the model's performance may be sensitive to the specific quantum hardware and software stack utilized, and that additional optimization and fine-tuning may be required for different drug discovery datasets and use cases.
Additionally, the authors do not provide a detailed analysis of the model's computational complexity and resource requirements, which would be important for assessing its practical feasibility and scalability in real-world drug discovery pipelines. Further research is needed to better understand the tradeoffs between the model's performance improvements and its computational overhead.
It would also be valuable to see the model evaluated on a wider range of binding affinity prediction benchmarks, as well as comparisons to other state-of-the-art classical and hybrid approaches beyond just the baseline models considered in this paper. This could help provide a more comprehensive understanding of the model's relative strengths and weaknesses.
Overall, the research presented in this paper represents an interesting and promising step forward in the development of advanced machine learning techniques for binding affinity prediction in drug discovery. However, additional work is needed to fully validate the model's practical utility and identify any potential limitations or areas for further improvement.
Conclusion
This research paper introduces a novel hybrid quantum-classical deep learning model for binding affinity prediction, a critical task in the drug discovery process. By integrating 3D and spatial graph convolutional neural networks within an optimized quantum architecture, the model demonstrates improved prediction accuracy and more stable convergence compared to classical approaches.
The unique capabilities of quantum computing, such as inherent parallelism and the ability to handle high-dimensional data, are leveraged to enhance the model's performance on this challenging problem. While further research is needed to fully validate the model's practical utility, this work represents an important step forward in the development of advanced machine learning techniques for accelerating and improving drug discovery workflows.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
🧠
0
A hybrid quantum-classical fusion neural network to improve protein-ligand binding affinity predictions for drug discovery
L. Domingo, M. Chehimi, S. Banerjee, S. He Yuxun, S. Konakanchi, L. Ogunfowora, S. Roy, S. Selvaras, M. Djukic, C. Johnson
The field of drug discovery hinges on the accurate prediction of binding affinity between prospective drug molecules and target proteins, especially when such proteins directly influence disease progression. However, estimating binding affinity demands significant financial and computational resources. While state-of-the-art methodologies employ classical machine learning (ML) techniques, emerging hybrid quantum machine learning (QML) models have shown promise for enhanced performance, owing to their inherent parallelism and capacity to manage exponential increases in data dimensionality. Despite these advances, existing models encounter issues related to convergence stability and prediction accuracy. This paper introduces a novel hybrid quantum-classical deep learning model tailored for binding affinity prediction in drug discovery. Specifically, the proposed model synergistically integrates 3D and spatial graph convolutional neural networks within an optimized quantum architecture. Simulation results demonstrate a 6% improvement in prediction accuracy relative to existing classical models, as well as a significantly more stable convergence performance compared to previous classical approaches.
Read more9/4/2024
0
On Machine Learning Approaches for Protein-Ligand Binding Affinity Prediction
Nikolai Schapin, Carles Navarro, Albert Bou, Gianni De Fabritiis
Binding affinity optimization is crucial in early-stage drug discovery. While numerous machine learning methods exist for predicting ligand potency, their comparative efficacy remains unclear. This study evaluates the performance of classical tree-based models and advanced neural networks in protein-ligand binding affinity prediction. Our comprehensive benchmarking encompasses 2D models utilizing ligand-only RDKit embeddings and Large Language Model (LLM) ligand representations, as well as 3D neural networks incorporating bound protein-ligand conformations. We assess these models across multiple standard datasets, examining various predictive scenarios including classification, ranking, regression, and active learning. Results indicate that simpler models can surpass more complex ones in specific tasks, while 3D models leveraging structural information become increasingly competitive with larger training datasets containing compounds with labelled affinity data against multiple targets. Pre-trained 3D models, by incorporating protein pocket environments, demonstrate significant advantages in data-scarce scenarios for specific binding pockets. Additionally, LLM pretraining on 2D ligand data enhances complex model performance, providing versatile embeddings that outperform traditional RDKit features in computational efficiency. Finally, we show that combining 2D and 3D model strengths improves active learning outcomes beyond current state-of-the-art approaches. These findings offer valuable insights for optimizing machine learning strategies in drug discovery pipelines.
Read more7/30/2024
🔮
0
Improved prediction of ligand-protein binding affinities by meta-modeling
Ho-Joon Lee, Prashant S. Emani, Mark B. Gerstein
The accurate screening of candidate drug ligands against target proteins through computational approaches is of prime interest to drug development efforts. Such virtual screening depends in part on methods to predict the binding affinity between ligands and proteins. Many computational models for binding affinity prediction have been developed, but with varying results across targets. Given that ensembling or meta-modeling methods have shown great promise in reducing model-specific biases, we develop a framework to integrate published force-field-based empirical docking and sequence-based deep learning models. In building this framework, we evaluate many combinations of individual base models, training databases, and several meta-modeling approaches. We show that many of our meta-models significantly improve affinity predictions over base models. Our best meta-models achieve comparable performance to state-of-the-art deep learning tools exclusively based on structures, while allowing for improved database scalability and flexibility through the explicit inclusion of features such as physicochemical properties or molecular descriptors. Overall, we demonstrate that diverse modeling approaches can be ensembled together to gain improvement in binding affinity prediction.
Read more5/21/2024
🔮
0
From Static to Dynamic Structures: Improving Binding Affinity Prediction with Graph-Based Deep Learning
Yaosen Min, Ye Wei, Peizhuo Wang, Xiaoting Wang, Han Li, Nian Wu, Stefan Bauer, Shuxin Zheng, Yu Shi, Yingheng Wang, Ji Wu, Dan Zhao, Jianyang Zeng
Accurate prediction of protein-ligand binding affinities is an essential challenge in structure-based drug design. Despite recent advances in data-driven methods for affinity prediction, their accuracy is still limited, partially because they only take advantage of static crystal structures while the actual binding affinities are generally determined by the thermodynamic ensembles between proteins and ligands. One effective way to approximate such a thermodynamic ensemble is to use molecular dynamics (MD) simulation. Here, an MD dataset containing 3,218 different protein-ligand complexes is curated, and Dynaformer, a graph-based deep learning model is further developed to predict the binding affinities by learning the geometric characteristics of the protein-ligand interactions from the MD trajectories. In silico experiments demonstrated that the model exhibits state-of-the-art scoring and ranking power on the CASF-2016 benchmark dataset, outperforming the methods hitherto reported. Moreover, in a virtual screening on heat shock protein 90 (HSP90) using Dynaformer, 20 candidates are identified and their binding affinities are further experimentally validated. Dynaformer displayed promising results in virtual drug screening, revealing 12 hit compounds (two are in the submicromolar range), including several novel scaffolds. Overall, these results demonstrated that the approach offer a promising avenue for accelerating the early drug discovery process.
Read more9/4/2024